NCT00002074

Brief Summary

To compare the safety and effectiveness of fluconazole and amphotericin B as maintenance treatment for preventing the relapse of cryptococcal meningitis in patients with AIDS.

Trial Health

85
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
2 countries

39 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 2, 1999

Completed
1.8 years until next milestone

First Posted

Study publicly available on registry

August 31, 2001

Completed
Last Updated

June 24, 2005

Status Verified

May 1, 1990

First QC Date

November 2, 1999

Last Update Submit

June 23, 2005

Conditions

Keywords

AIDS-Related Opportunistic InfectionsMeningitisCryptococcosisFluconazoleAcquired Immunodeficiency SyndromeAmphotericin B

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Concurrent Medication:
  • Allowed:
  • Antivirals such as zidovudine.
  • Prophylaxis (including aerosolized pentamidine) for Pneumocystis carinii pneumonia (PCP).
  • Pfizer must be notified if the patient is receiving ganciclovir (DHPG) at entry.
  • Concurrent Treatment:
  • Allowed:
  • Radiation therapy for mucocutaneous Kaposi's sarcoma.
  • Patients must be oriented to person, place, and time, and able to give written informed consent.
  • Patients must have had an acute episode of cryptococcal meningitis that was documented by recovery and identification of Cryptococcus neoformans from lumbar cerebrospinal fluid (CSF) culture within 6 months prior to entry.
  • Minimum total dose of 15 mg/kg of amphotericin B must have been given (either alone or in combination with flucytosine) during primary therapy.
  • Patients need not be receiving amphotericin B at the time of randomization but must begin study maintenance therapy within 6 weeks of completion of primary amphotericin B therapy. Patients may receive maintenance amphotericin B during the period between completion of primary therapy and study entry.
  • Prior Medication:
  • Allowed:
  • Antivirals such as zidovudine (AZT).
  • +1 more criteria

You may not qualify if:

  • Co-existing Condition:
  • Patients with the following are excluded:
  • Clinical evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis.
  • History of allergy or intolerance of imidazoles, azoles, or amphotericin B.
  • Moderate or severe liver disease.
  • Concurrent Medication:
  • Excluded:
  • Ketoconazole.
  • Fluconazole.
  • Itraconazole.
  • Miconazole.
  • Any systemic imidazole or azole for more than 7 days after initiation of primary therapy for cryptococcosis.
  • Intrathecal amphotericin B.
  • Coumarin-type anticoagulants.
  • Oral hypoglycemics.
  • +30 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (39)

Univ of Alabama at Birmingham

Birmingham, Alabama, 35294, United States

Location

Tucson Veterans Administration Med Ctr

Tucson, Arizona, 85724, United States

Location

Dr Richard Meyer

Los Angeles, California, 90048, United States

Location

Davies Med Ctr

San Francisco, California, 94114, United States

Location

Dr Paul Rothman

Sherman Oaks, California, 91403, United States

Location

Wilmington Hosp / Med Ctr of Delaware

Wilmington, Delaware, 19899, United States

Location

George Washington Univ Med Ctr

Washington D.C., District of Columbia, 20037, United States

Location

Univ of Florida College of Medicine

Gainesville, Florida, 32610, United States

Location

Univ of South Florida

Tampa, Florida, 33612, United States

Location

Emory Univ School of Medicine

Atlanta, Georgia, 30303, United States

Location

Med College of Georgia

Augusta, Georgia, 30912, United States

Location

DeKalb Gen Hosp

Decatur, Georgia, 30033, United States

Location

Shallowford Hosp

Decatur, Georgia, 30033, United States

Location

Northwestern Univ Med School

Chicago, Illinois, 60611, United States

Location

Dr Michael Bach

Portland, Maine, 04102, United States

Location

Univ of Maryland / Inst of Human Virology

Baltimore, Maryland, 212011192, United States

Location

New England Med Ctr

Boston, Massachusetts, 02111, United States

Location

Univ Hosp

Boston, Massachusetts, 02118, United States

Location

Ann Arbor Veterans Administration Med Ctr

Ann Arbor, Michigan, 48105, United States

Location

Harper Hosp

Detroit, Michigan, 48201, United States

Location

Henry Ford Hosp

Detroit, Michigan, 48202, United States

Location

Saint Michael's Med Ctr

Newark, New Jersey, 07102, United States

Location

Albany Med College / AIDS Treatment Ctr

Albany, New York, 12203, United States

Location

Jewish Hosp Ctr Affiliation

Jamaica, New York, 11432, United States

Location

Cabrini Med Ctr

New York, New York, 10003, United States

Location

Chelsea Village Med Ctr

New York, New York, 10014, United States

Location

Columbia Univ

New York, New York, 10032, United States

Location

Harlem AIDS Treatment Group / Harlem Hosp Ctr

New York, New York, 10037, United States

Location

Bowman Gray School of Medicine / North Carolina Baptist Hosp

Winston-Salem, North Carolina, 27103, United States

Location

Cincinnati Veterans Adm Med Ctr / Univ Hosp

Cincinnati, Ohio, 452670405, United States

Location

Buckley Braffman Stern Med Associates

Philadelphia, Pennsylvania, 19107, United States

Location

Univ TX Galveston Med Branch

Galveston, Texas, 77550, United States

Location

United States Air Force Med Ctr

Lackland Air Force Base, Texas, 782365300, United States

Location

Southwest Texas Methodist Hosp

San Antonio, Texas, 78229, United States

Location

Univ TX San Antonio Health Science Ctr

San Antonio, Texas, 78284, United States

Location

Richmond AIDS Consortium

Richmond, Virginia, 23219, United States

Location

CHG-118 Group Health / Cooperative of Puget Sound

Seattle, Washington, 98112, United States

Location

Dr Philip C Craven

Tacoma, Washington, 98405, United States

Location

Saint Michael's Hosp

Toronto, Ontario, Canada

Location

Related Publications (2)

  • Powderly WG, Saag MS, Cloud GA, Robinson P, Meyer RD, Jacobson JM, Graybill JR, Sugar AM, McAuliffe VJ, Follansbee SE, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med. 1992 Mar 19;326(12):793-8. doi: 10.1056/NEJM199203193261203.

    PMID: 1538722BACKGROUND
  • Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, Thompson SE, Sugar AM, Tuazon CU, Fisher JF, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med. 1992 Jan 9;326(2):83-9. doi: 10.1056/NEJM199201093260202.

    PMID: 1727236BACKGROUND

MeSH Terms

Conditions

Meningitis, CryptococcalHIV InfectionsAIDS-Related Opportunistic InfectionsMeningitisCryptococcosisAcquired Immunodeficiency Syndrome

Interventions

FluconazoleAmphotericin B

Condition Hierarchy (Ancestors)

Meningitis, FungalCentral Nervous System Fungal InfectionsMycosesBacterial Infections and MycosesInfectionsCentral Nervous System InfectionsCentral Nervous System DiseasesNervous System DiseasesNeuroinflammatory DiseasesBlood-Borne InfectionsCommunicable DiseasesSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesOpportunistic InfectionsSlow Virus Diseases

Intervention Hierarchy (Ancestors)

TriazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsMacrolidesPolyketidesLactonesOrganic Chemicals

Study Design

Study Type
interventional
Phase
not applicable
Purpose
TREATMENT
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

November 2, 1999

First Posted

August 31, 2001

Last Updated

June 24, 2005

Record last verified: 1990-05

Locations